(UroToday.com) Dr. Franklin Huang focused his presentation on the role of genomic testing in metastatic prostate cancer and how it influences therapeutic decision-making for medical oncologists. He specifically focused on genomic testing for microsatellite instability, tumor mutational burden, and DNA damage repair deficiency and the role of immunotherapy and PARP inhibitors for these alterations.